NKTR (STOCKS)
Nektar Therapeutics
$61.145000
+1.765000 (+2.97%)
Prev close: $59.380000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Howard W. Robin
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,067.03M
- Employees
- 61
- P/E (TTM)
- -7.26
- P/B (TTM)
- 2.10
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
7
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.82 | $-1.63 | -0.1933 | -11.88% |
|
Dec 2025 (Q4)
|
$-1.78 | $-2.52 | +0.7436 | +29.47% |
|
Sep 2025 (Q3)
|
$-1.87 | $-2.74 | +0.8682 | +31.71% |
|
Jun 2025 (Q2)
|
$-2.95 | $-3.10 | +0.1457 | +4.71% |
Financial Statements
| Revenues | $55.63M |
| Benefits Costs and Expenses | $216.57M |
| Costs And Expenses | $190.25M |
| Nonoperating Income/Loss | -$17.59M |
| Operating Expenses | $190.25M |
| Depreciation and Amortization | $751.00K |
| Research and Development | $122.53M |
| Other Operating Expenses | $67.38M |
| Operating Income/Loss | -$134.62M |
| Income/Loss Before Equity Method Investments | -$152.21M |
| Income/Loss From Continuing Operations After Tax | -$160.81M |
| Income/Loss From Continuing Operations Before Tax | -$160.94M |
| Income/Loss From Equity Method Investments | -$6.02M |
| Income Tax Expense/Benefit | -$126.00K |
| Net Income/Loss | -$158.10M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$158.10M |
| Net Income/Loss Available To Common Stockholders, Basic | -$158.10M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$8.23 |
| Diluted Earnings Per Share | -$8.23 |
| Basic Average Shares | 58,924,466 |
| Diluted Average Shares | 58,924,466 |
| Assets | $763.27M |
| Current Assets | $589.04M |
| Noncurrent Assets | $174.23M |
| Liabilities | $187.06M |
| Current Liabilities | $57.71M |
| Accounts Payable | $10.03M |
| Wages | $5.01M |
| Other Current Liabilities | $42.67M |
| Noncurrent Liabilities | $129.35M |
| Equity | $576.22M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $576.22M |
| Liabilities And Equity | $763.27M |
| Net Cash Flow From Operating Activities | -$203.76M |
| Net Cash Flow From Operating Activities, Continuing | -$203.76M |
| Net Cash Flow From Investing Activities | -$395.68M |
| Net Cash Flow From Investing Activities, Continuing | -$395.68M |
| Net Cash Flow From Financing Activities | $710.11M |
| Net Cash Flow From Financing Activities, Continuing | $710.11M |
| Exchange Gains/Losses | $7.00K |
| Net Cash Flow | $110.68M |
| Net Cash Flow, Continuing | $110.68M |
| Comprehensive Income/Loss | -$159.17M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$159.17M |
| Other Comprehensive Income/Loss | -$1.07M |